-
The joint prevention and control mechanism of the State Council responds to whether to adjust the prevention and control policy
Time of Update: 2022-11-15
health At present, the international epidemic has ushered in a new winter epidemic season, and the rebound trend of the epidemic in some parts of the country is obvious, superimposed on the risk of influenza and other respiratory diseases, and the epidemic situation is more severe and complex.
-
In order to strengthen the coverage and extension of products and businesses, pharmaceutical companies are constantly "buying, buying and buying"
Time of Update: 2022-11-15
js?cdnversion='+~(-new Date()/36e5)];Extending the industrial chain or expanding the product line through investment, acquisition and other means has become the norm in the pharmaceutical field.
js?cdnversion='+~(-new Date()/36e5)];Extending the industrial chain or expanding the product line through investment, acquisition and other means has become the norm in the pharmaceutical field.
-
Traditional Chinese medicine formula granules stand on the development vent, and such enterprises will seize the opportunity
Time of Update: 2022-11-15
js?cdnversion='+~(-new Date()/36e5)];In the process of transformation from enterprise standard products to national standard and provincial standard products, the standard improvement leads to costs, and the gross profit margin level has declined to a certain extent.
-
In November, a number of new drug clinical applications have been approved
Time of Update: 2022-11-15
On November 2, Acro Biotech announced that the clinical trial application of the new PD-L1/4-1BB bispecific antibody "HK010 injection" with independent intellectual property rights has been approved by the State Food and Drug Administration and is intended to be used for the treatment of advanced malignant tumors.
-
Another IND application for a new stem cell drug from Heinz Pharmaceuticals was accepted
Time of Update: 2022-11-15
Acceptance number: CXSL2200553Drug Name: Mesenchymal stem cells for injection (umbilical cord)Type of drug: Therapeutic biological productsApplication type: New drugRegistration classification: 1 categoryUmbilical cord mesenchymal stem cells belong to perinatal stem cells, which have the characteristics of strong proliferation and differentiation ability, abundant quantity, more vitality, low immunogenicity, reuse of waste tissue, no ethical barriers, easy to standardize preparation, etc.
-
This pharmaceutical company, whose net profit increased by more than 66%, has 19 Class 1 new drugs in the stage of clinical application and above
Time of Update: 2022-11-15
js?cdnversion='+~(-new Date()/36e5)];Kelun Pharmaceutical released the third quarterly report of 2022 on the evening of October 30, and the company's total operating income in the first three quarters was 13.
-
Announcement of the State Food and Drug Administration on amending the instructions of the oral preparation of methotrexate
Time of Update: 2022-11-15
） According to the results of adverse drug reaction assessment, in order to further protect the safety of public drug use, the State Medical Products Administration decided to uniformly revise the content of the instructions of the oral preparation of methotrexate.
-
Domestic pharmaceutical companies have devoted themselves to the research and development of bispecific antibody drugs, and two companies have made new progress
Time of Update: 2022-11-15
On November 1, the website of the Center for Drug Evaluation of the National Medical Products Administration announced that the clinical trial application of AK129 injection declared by Akeso Biologics has been implicitly approved, and the innovative drug is LAG-3 (lymphocyte activation gene 3)/PD-1 (programmed death protein 1) biantibody, which is intended to be developed for the treatment of advanced malignant tumors.
-
Another deputy general manager of a pharmaceutical company, join the resignation team!
Time of Update: 2022-11-15
js?cdnversion='+~(-new Date()/36e5)];Another deputy general manager of a pharmaceutical company, join the resignation team!
js?cdnversion='+~(-new Date()/36e5)];Another deputy general manager of a pharmaceutical company, join the resignation team!
js?cdnversion='+~(-new Date()/36e5)];Another deputy general manager of a pharmaceutical company, join the resignation team!
-
In November, a number of pharmaceutical executives left, half of which were deputy general managers
Time of Update: 2022-11-15
According to the third quarterly report of 2022, the company achieved total operating income of 710 million yuan in the first three quarters of 2022, a year-on-year increase of 15.
-
33 exclusive proprietary Chinese medicines are lit up! The two major varieties will exceed 1 billion for the first time
Time of Update: 2022-11-15
33 exclusive proprietary Chinese medicines are sold together for nearly 20 billion, and 2 new 1 billion single products will be born In 2022E, the total sales scale of 33 exclusive proprietary Chinese medicines with terminal sales of more than 300 million yuan in China's urban physical pharmacies is close to 20 billion yuan, a year-on-year increase of about 4.
-
Since November, a large number of pharmaceutical companies have been suspended and stopped operating!
Time of Update: 2022-11-15
With the tightening of supervision in the pharmaceutical industry, cases of pharmaceutical companies being punished have been occurring from time to time. It is reported that recently, many local dru
-
How to solve the financing difficulty? Pharmaceutical companies have "huddled together", and 235 mergers and acquisitions have occurred in the first three quarters
Time of Update: 2022-11-15
Since the end of 2021, the biopharmaceutical industry has generally faced a slowdown in financing and cooperation, in addition, in the innovative drug track, the current homogenization of innovative drug research and development is more serious, coupled with the new medical reform environment background of tightening medical insurance control fees and centralized procurement and price reduction, in order to survive the cold winter, many pharmaceutical companies have "huddled together" through mergers and acquisitions and restructuring in 2022.
-
The R&D and innovation of pharmaceutical companies has become a boom, forcing the pharmaceutical equipment industry to accelerate upgrading
Time of Update: 2022-11-15
In recent years, many departments of the state are continuously introducing a series of favorable policies such as optimizing the review and approval system, launching "major new drug creation", and simplifying clinical trial approval procedures to promote the upgrading and transformation of the domestic pharmaceutical industry from generic drugs to innovative drugs, and encourage more new drugs with clinical value to quickly enter the clinical stage.
-
455 pharmaceutical companies achieved revenue of 1.81 trillion yuan, and the "revenue king" was settled
Time of Update: 2022-11-14
102 billion yuan, a year-on-year increase of more than 20%; WuXi AppTec achieved a net profit attributable to the parent of about 7.
102 billion yuan, a year-on-year increase of more than 20%; WuXi AppTec achieved a net profit attributable to the parent of about 7.
-
15 provincial alliances collect and point to unevaluated varieties, and injections are the focus! What is the proportion of price factors?
Time of Update: 2022-11-14
On November 1 and 2, the official website of the State Food and Drug Administration successively released an announcement on the revision of drug instructions for a number of injection products, invo
-
The "pharmaceutical" brother was increased by the public fund, what signal was released?
Time of Update: 2022-11-14
In the 2022 half-year report, the company has stated that the centralized procurement of generic drugs, the price reduction of innovative drugs due to the implementation of new medical insurance negotiations, and the reduction of the daily diagnosis and treatment business volume of medical institutions due to the epidemic have all affected revenue, in addition, the increase in raw material prices, logistics costs, capacity utilization rates, and increased R&D investment have affected the profit of the current period.
-
The cephalosporin market has changed dramatically! Beite new TOP10 Kelun exclusive new products welcome benefits
Time of Update: 2022-11-14
Source: Intranet database comprehensive collation Cefoperadone sulbactam, cefoxitin, cefotaxime, cefodizime and cefotian in 2021 in China's public medical institutions terminal sales of more than 1 billion yuan, at present, no products have been included in the national procurement, 5 large varieties of cephalosporin injections have been evaluated by more than 4 enterprises, is the eighth batch of national hot varieties.
-
NMPA: Revised the drug instructions for astragalus polysaccharides for injection and sodium chloride injection for lampflowerin!
Time of Update: 2022-11-14
01Original text of the notice According to the results of the adverse drug reaction assessment, in order to further protect the safety of public drug use, the State Medical Products Administration decided to uniformly revise the warning words and [adverse reactions], [contraindications] and [precautions] in the instructions of astragalus polysaccharides for injection, sodium chloride injection and banlangen injection.
-
The layout of domestic CAR-T enterprises is in full swing, with new breakthroughs and new progress!
Time of Update: 2022-11-14
According to reports, Hekilenxel is the first CAR-T product in the field of leukemia in China to reach the main clinical research endpoint, and it is expected to provide effective treatment for adult r/r B-ALL patients after marketing.
